- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00963924
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
D-cycloserine has been shown to enhance learning in animal models and, in a previous trial, once-weekly D-cycloserine improved negative symptoms in schizophrenia subjects. We set out to test whether DCS combined with cognitive remediation would improve learning of a practiced auditory discrimination task and whether gains would generalize to unpracticed cognitive tasks.
The proposed study consists of an 8-week, placebo-controlled, double-blind, parallel-group trial of D-cycloserine augmentation of cognitive remediation in schizophrenia outpatients. The primary outcome measure is change in performance on the MATRICS cognitive battery composite score after 8 weeks. Secondary outcome measures include a measure of processing speed assessed after weeks 1, 2, 4 & 8, and changes in negative symptoms and measures of functioning after 4 and 8 weeks. In addition, all outcome measures will be repeated at 6 months to assess persistence of benefit.
Hypotheses:
- D-cycloserine will significantly improve cognitive performance as measured by the composite score on the MATRICS battery compared to placebo after 8 weeks of cognitive remediation.
- D-cycloserine will significantly improve negative symptoms as measured by the SANS compared to placebo after 8 weeks when combined with cognitive remediation.
- D-cycloserine will significantly improve measures of functioning (GAS, QoL and CGI) at 8 weeks compared to placebo when combined with cognitive remediation.
- D-cycloserine effects on cognition, negative symptoms and functioning will persist compared to placebo when assessed at 6-month follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Age 18-65 years
- Diagnosis of schizophrenia or schizoaffective disorder, depressed type
- Stable dose of antipsychotic for at least 4 weeks
- Able to provide informed consent
- Able to complete a cognitive battery
- Able to perform the cognitive remediation exercises
Exclusion Criteria:
- Current treatment with clozapine
- Dementia
- Seizure disorder
- Unstable medical illness
- Renal insufficiency measured as eGFR >60mg/dL/min
- Active substance abuse: positive urine toxic screen
- Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: D-cycloserine
Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
|
50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
Other Names:
40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
Other Names:
|
Placebo Comparator: Placebo
Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
|
40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
Other Names:
Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
Time Frame: Baseline vs. Week 8
|
Change of a composite score from baseline to week 8 on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS).
The MATRICS consists of 10 cognitive tasks that are used to calculate scores in 7 cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition.
The raw scores on each cognitive task are transformed on a normative scale into t-scores, and then these scores are combined to calculate the domain scores.
The composite score is calculated by averaging all domain t-scores to come up with one overall cognitive composite t-score.
For all scores on the assessment, the higher the score the better the performance on the task.
|
Baseline vs. Week 8
|
Scale for Assessment of Negative Symptoms (SANS)
Time Frame: Baseline vs. Week 8
|
The total scores from baseline and week 8 on the scale for the assessment of negative symptoms (SANS) total score.
Total SANS scores range from 0-100.
The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10).
For each scale, the higher the score the more prominent the negative symptoms were.
The total score was computed by adding all the sub-scale total scores.
Scores are reported for baseline and week 8.
|
Baseline vs. Week 8
|
Auditory Discrimination Task: Interstimulus Interval (ISI)
Time Frame: Baseline vs. Week 8
|
The auditory discrimination task involved trials in which the subject differentiated between rapidly-presented frequency-modulated sweeps separated by a short interstimulus interval (ISI).
In this task, sustained successful performance is more difficult with shorter stimulus presentations and ISIs (which were equal within a trial).
Thus, our dependent measure was the shortest stimulus duration/ISI, in ms, for trials in which subjects were able to perform the task at 85% accuracy, referred to as ISI for simplicity.
The shorter the score the better the performance on the task.
Scores are reported for baseline and week 8.
|
Baseline vs. Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Time Frame: Baseline
|
The baseline score on the positive symptom sub-scale of the Positive and Negative Syndrome Scale (PANSS).
Total PANSS positive symptom sub-scale scores range from 7-49.
The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.
A score of one on each item 1 absent, 2 is minimal, 3 is mild, 4 is moderate, 5 is moderately severe, 6 is severe, and 7 is extreme.
The total score was computed by adding all the items on the sub-scale together.
The higher a score the more prominent a positive symptom is.
|
Baseline
|
Global Assessment of Functioning Scale (GAS)
Time Frame: Baseline
|
The Global Assessment of Functioning Scale (GAS) measured at baseline.
This scale measures social, occupational, and psychological functioning, on a scale of 0-100.
The higher the score, the greater a participant's functioning level.
|
Baseline
|
Heinrich Quality of Life Scale (QoL)
Time Frame: Baseline
|
Baseline scores of the Heinrich Quality of Life Scale, a 21 item scale designed and validated to measure intrapsychic foundations, interpersonal relations, instrumental role, and common objects and activities in patients diagnosed with Schizophrenia.
Patients are rated on each of the 21 items on a scale of 0-6.
Total scores are computed by adding up the scores of each individual item, with a total score ranging from 0-126.
Higher scores reflect higher functioning.
|
Baseline
|
Calgary Depression Scale for Schizophrenia (CDSS)
Time Frame: Baseline
|
Baseline scores on the Calgary Depression Scale for Schizophrenia (CDSS).
Total CDSS scores range from 0-27.
The assessment is comprised of 9 questions covering the topics of Depression, Hopelessness, Self Depreciation, Guilty Ideas of Reference, Pathological Guilt, Morning Depression, Early Wakening, Suicide, Observed Depression.
Each item is scored on a scale from 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
The total score is computed by adding up the individual scores of each item.
The higher the score, the more prominent the symptoms of depression are for the participant.
|
Baseline
|
Clinical Global Impression (CGI)
Time Frame: Weeks 0 and 8, and Month 6 after cognitive remediation completion
|
Considering you total clinical experience with this patient population, how mentally ill is the patient at this time? 1=Normal, not at all, 2=Borderline mentally ill, 3=Mildy ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, 7=Among the most extremely ill patients; a higher score indicates worse outcome |
Weeks 0 and 8, and Month 6 after cognitive remediation completion
|
Side Effects Checklist (SEC)
Time Frame: Weeks 0 - 8, and Month 6 after cognitive remediation completion
|
Each side effect is entered as either yes or no for having had any severity of the side effect at each visit.
|
Weeks 0 - 8, and Month 6 after cognitive remediation completion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Donald C. Goff, M.D., Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008P002237
- DATR A3-NSC (National Institute of Mental Health)
- 5P50MH060450 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on D-cycloserine
-
Mclean HospitalUniversity of MinnesotaCompletedSchizophrenia | Bipolar Disorder
-
University of Texas at AustinBoston University; Rush University Medical Center; Southern Methodist UniversityCompletedSocial Anxiety DisorderUnited States
-
University of OxfordNational Health Service, United KingdomUnknownChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedChronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
-
Yale UniversityCompletedAlcohol DependenceUnited States
-
University of California, Los AngelesUnknownTraumatic Brain InjuryUnited States
-
US Department of Veterans AffairsCompleted
-
University of ArkansasNational Institute on Drug Abuse (NIDA)Completed
-
Northwestern UniversityTerminatedPain | Breast Cancer | NeurotoxicityUnited States
-
Hoffmann-La RocheCompletedHepatitis C, ChronicNew Zealand, Australia